Welcome to our dedicated page for Biolife Solutions news (Ticker: BLFS), a resource for investors and traders seeking the latest updates and insights on Biolife Solutions stock.
BioLife Solutions Inc (NASDAQ: BLFS) maintains industry leadership through innovative biopreservation solutions for cell and gene therapies. This dedicated news hub provides comprehensive updates on corporate developments, regulatory milestones, and technological advancements essential for stakeholders in the life sciences sector.
Access official press releases covering quarterly earnings, strategic partnerships, and product innovations in cryopreservation media and cold chain management systems. Our curated collection serves investors and researchers requiring timely, accurate information about BLFS's role in advancing biologic manufacturing infrastructure.
The resource prioritizes updates on BioLife's core competencies: clinical-grade cell processing tools, smart shipper technologies, and quality assurance protocols critical for therapy commercialization. Content spans regulatory filings, manufacturing expansions, and intellectual property developments shaping the biostorage industry.
For consistent monitoring of BioLife's market position, bookmark this page or subscribe to Stock Titan's update alerts. All materials maintain strict editorial standards to support informed decision-making in the rapidly evolving cell therapy landscape.
BioLife Solutions reported a record full year revenue of $161.8 million for 2022, marking a 36% increase from 2021, with biopreservation media revenue growing by 45%. Q4 2022 revenue reached $44.3 million, up 19% year-on-year. Adjusted EBITDA for the year was $3.6 million, and for Q4, it was $1.7 million. The company anticipates 2023 revenue between $188 million and $202 million, reflecting growth rates of 16% to 25%. CEO Mike Rice emphasized continued demand for their products in the growing cell and gene therapy markets, with expected revenue growth largely driven by cell processing platforms and storage services.
BioLife Solutions (NASDAQ: BLFS) has addressed its banking relationship with Silicon Valley Bank (SVB) amid recent concerns. The company states there is no immediate risk to its operations, with deposit accounts at SVB below $1 million, well within FDIC insurance limits. BioLife also mentions that its credit facility with SVB remains under assessment but anticipates no short-term borrowing needs. Furthermore, various other institutions manage their third-party investments, mitigating potential liquidity issues linked to SVB.
BioLife Solutions (NASDAQ: BLFS) will release its fourth quarter and full year 2022 financial results after market close on March 16, 2023. The company will also host a conference call at 4:30 PM ET to discuss these results and provide a general business update. Investors can access the call via BioLife's Investor Relations page or by dialing in. The results are critical as they will reflect BioLife's performance in the rapidly evolving cell and gene therapy market, where it supplies bioproduction tools and services. The conference call will also include insights into the company's future outlook.
FAQ
What is the current stock price of Biolife Solutions (BLFS)?
What is the market cap of Biolife Solutions (BLFS)?
